{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:30:34Z","timestamp":1759991434633,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.medmal.2006.09.001","type":"journal-article","created":{"date-parts":[[2006,11,8]],"date-time":"2006-11-08T07:30:00Z","timestamp":1162971000000},"page":"505-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tol\u00e9rance cardiaque de\u00a0la\u00a0moxifloxacine : exp\u00e9rience clinique issue d'une large \u00e9tude observationnelle fran\u00e7aise en\u00a0pratique m\u00e9dicale usuelle (\u00e9tude IMMEDIAT)"],"prefix":"10.1016","volume":"36","author":[{"given":"P.","family":"Veyssier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Voirot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Begaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Funck-Brentano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2006.09.001_bib1","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2165\/00003495-200464200-00006","article-title":"Moxifloxacin. A review of its use in the management of bacterial infections","volume":"64","author":"Keating","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2006.09.001_bib2","unstructured":"Bayer Pharma. R\u00e9sum\u00e9 des caract\u00e9ristiques du produit (RCP) Moxifloxacine, vidal 2006"},{"key":"10.1016\/j.medmal.2006.09.001_bib3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00003495-200464100-00005","article-title":"QT prolongation with antimicrobial agents. Understanding the significance","volume":"64","author":"Owens","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2006.09.001_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.medmal.2006.09.001_bib5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0149-2918(04)90170-1","article-title":"Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies","volume":"26","author":"Ball","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.medmal.2006.09.001_bib6","article-title":"The Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","volume":"E14","year":"2004","journal-title":"ICH"},{"key":"10.1016\/j.medmal.2006.09.001_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2003.04.055","article-title":"Torsade de pointes: the clinical considerations","volume":"96","author":"Gowda","year":"2004","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.medmal.2006.09.001_bib8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1592\/phco.23.7.881.32730","article-title":"Clinical relevance and management of drug-related QT interval prolongation","volume":"23","author":"Crough","year":"2003","journal-title":"Pharmacother."},{"issue":"suppl.","key":"10.1016\/j.medmal.2006.09.001_bib9","first-page":"34","article-title":"Fluoroquinolone toxicity: a review of class-and agent-specific adverse effects","author":"Iannini","year":"2004","journal-title":"Drugs Benefit Trends."},{"key":"10.1016\/j.medmal.2006.09.001_bib10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/archinte.164.9.943","article-title":"Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. A review and qualitative overview of prospective cohort studies","volume":"164","author":"Montanez","year":"2004","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.medmal.2006.09.001_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","article-title":"Anti HERG activity and the risk of drug-induced arrhythmias and sudden death","author":"De Bruin","year":"2005","journal-title":"Eur. Heart J."},{"issue":"26","key":"10.1016\/j.medmal.2006.09.001_bib12","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/eurheartj\/ehi312","article-title":"Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death","volume":"11","author":"Straus","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.medmal.2006.09.001_bib13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa040582","article-title":"Oral erythromycin and the risk of sudden death from cardiac causes","volume":"351","author":"Ray","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medmal.2006.09.001_bib14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mcp.2000.111482","article-title":"Effect of a single oral dose of moxifloxacin (400mg and 800mg) on ventricular repolarization in healthy subjects","volume":"68","author":"Demolis","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medmal.2006.09.001_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14740338.1.2.121","article-title":"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval","volume":"1","author":"Iannini","year":"2002","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.medmal.2006.09.001_bib16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0149-2918(00)88291-0","article-title":"Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis","volume":"21","author":"Henry","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.medmal.2006.09.001_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0149-2918(00)88271-5","article-title":"Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia","volume":"21","author":"Ramirez","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.medmal.2006.09.001_bib18","unstructured":"Ross D. Telithromycin (KETEK\u2122): General safety profile. Anti-infective Drugs Advisory Committee April 26, 2001. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/01\/slides\/3746s_05_Ross\/sld024.htm."},{"year":"2000","series-title":"QTc prolongation associated with levofloxacin","author":"Iannini","key":"10.1016\/j.medmal.2006.09.001_bib19"},{"key":"10.1016\/j.medmal.2006.09.001_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1592\/phco.21.3.301.34206","article-title":"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes","volume":"21","author":"Owens","year":"2001","journal-title":"Pharmacother."},{"key":"10.1016\/j.medmal.2006.09.001_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/0897190003257626","article-title":"What role do fluoroquinolone antimicrobial agents play in cardiac dysfunction and altered glycemic control?","volume":"16","author":"Smith","year":"2003","journal-title":"J. Pharmacol. Pract."},{"key":"10.1016\/j.medmal.2006.09.001_bib22","doi-asserted-by":"crossref","first-page":"253S","DOI":"10.1592\/phco.21.16.253S.33993","article-title":"Fluoroquinolone adverse effects and drug interaction","volume":"21","author":"Fish","year":"2001","journal-title":"Pharmacother."},{"key":"10.1016\/j.medmal.2006.09.001_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0009-9236(96)90105-8","article-title":"Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram","volume":"59","author":"Benton","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medmal.2006.09.001_bib24","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.1993.03500120070028","article-title":"Mechanism of the cardiotoxic actions of terfenadine","volume":"269","author":"Woosley","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.medmal.2006.09.001_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.1C066","article-title":"Clinical experience with moxifloxacin in patients with respiratory tract infections","volume":"38","author":"Faisch","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.medmal.2006.09.001_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2165\/00044011-200121120-00002","article-title":"Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia","volume":"21","author":"Landen","year":"2001","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.medmal.2006.09.001_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200323010-00001","article-title":"Efficacy and tolerability of moxifloxacin in 2338 ptients with acute exacerbation of chronic bronchitis","volume":"23","author":"Barth","year":"2003","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.medmal.2006.09.001_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00044011-200424080-00003","article-title":"Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany","volume":"24","author":"Koch","year":"2004","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.medmal.2006.09.001_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.clpt.2003.11.376","article-title":"Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors","volume":"75","author":"Amankwa","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medmal.2006.09.001_bib30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medmal.2006.09.001_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1472-8206.2002.00083.x","article-title":"Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity","volume":"16","author":"Shah","year":"2002","journal-title":"Fundament. Clin. Pharmacol."},{"key":"10.1016\/j.medmal.2006.09.001_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199550010-00001","article-title":"Gender as a risk factor for adverse events to medications","volume":"50","author":"Kando","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2006.09.001_bib33","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1046\/j.1532-5415.2002.50607.x","article-title":"Adverse drug reactions as cause of hospital admissions: results from the italian Group of Pharmacoepidemiology in the elderly (GIFA)","volume":"50","author":"Onder","year":"2002","journal-title":"Geriatr. Soc."},{"key":"10.1016\/j.medmal.2006.09.001_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.2000.00132.x","article-title":"Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine","volume":"49","author":"Fattinger","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.medmal.2006.09.001_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","article-title":"Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France","volume":"16","author":"Montastruc","year":"2002","journal-title":"Fundam. Clin. Pharmacol."}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06002617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X06002617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:01:19Z","timestamp":1759971679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X06002617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0399077X06002617"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2006.09.001","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tol\u00e9rance cardiaque de\u00a0la\u00a0moxifloxacine: exp\u00e9rience clinique issue d'une large \u00e9tude observationnelle fran\u00e7aise en\u00a0pratique m\u00e9dicale usuelle (\u00e9tude IMMEDIAT)","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2006.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}